Persistent Antidementia Drug Treatment and Survival in an Alzheimer's Disease (AD) Cohort

Susan Rountree, MD; Valory Pavlik, PhD; Wenyaw Chan, PhD; Rachelle Doody, MD, PhD

Background

- Survival (life span) in people with AD is recognized to be shorter than what is expected in cognitively normal seniors and is recognized to be influenced by several factors including age, disease severity, general debility, and gender.
- An estimate of survival probability among patients with AD is needed for planning and assessing the overall impact of dementia.
- Since 1993 five drugs have been marketed in the U.S. for the treatment of Alzheimer's disease (donepezil, galantamine, rivastigmine, tacrine, memantine).
- Antidementia drugs have been proven to help with the symptoms of Alzheimer's disease but their influence on long term course and life span is not known. We previously presented data that showed cognitive and functional benefits continued over many years for patients who persist in their treatment.
- This study examined the use of antidementia drugs or more precisely, the persistent use of these medications and their influence on survival. This information is not available for clinical trial data because such studies have a relatively short duration of follow-up.

Methods

- PROSPECTIVE COHORT STUDY — Probable AD patients (meeting NINCDS-ADRDA criteria) followed at the Baylor College of Medicine Alzheimer's Disease Center. The longitudinal database is approved by the IRB.
- PATIENTS — Diagnosis of probable AD with no confounding secondary diagnoses and with follow-up visits that have records of total lifetime antidementia medication exposure.
- INDEPENDENT VARIABLE — Treatment with antidementia medication. We evaluated drug exposure or cumulative time on drug from the onset of symptoms and determined a persistency score.
- COVARIATES — Age, sex, years of education, duration of symptoms, and baseline severity of their initial mild, moderate, severe were based on Mini Mental Status Examination score (MMSE), and an indicator variable reflecting whether or not a patient had started on antidementia therapy before their initial visit to the ADMDC. We also evaluated the progression rate calculated by the following formula: (MMSE score (expected 30) - MMSE score (initial) / physician's estimate of symptom duration (in years)) in another model which excluded the duration of symptoms and baseline severity.
- ANALYSIS — Proportional hazards regression method was used to determine the association of drug treatment category (persistent score) and all-cause mortality using the upper quartile of drug persistency as the reference. Adjustments were made for the other covariates. Median survival times were calculated. The cut-off date for data analysis was December 31, 2005.

Results

- Greater persistent therapy with antidementia drugs was significantly associated with prolonged survival in an AD cohort with adjustment for covariates.
- Persistent drug therapy appears to help Alzheimer's patients live longer and the mechanism may be related to overall improvement of cognition and function resulting from current symptomatic therapies.
- Additional studies are needed to confirm these results.

Introduction

- Large number of patients followed over a relatively long period
- Reflects actual clinical practice, as patients came to the center at various times following first symptoms and were often treated in the community initially.

Limitations

- Observational study
- Selection factors associated with long term drug use cannot be ruled out as an alternative explanation for the findings
- High dose vitamin E use as part of an antidementia drug regimen was recently reported to be associated with improved survival in a long term study, and many of our patients also take high dose vitamin E. The present study was limited to use of prescription drugs approved for AD treatment.

Conclusions

- Greater persistent therapy with antidementia drugs was significantly associated with prolonged survival in an AD cohort with adjustment for covariates.

Survival Distribution Function

- 641 patients met inclusion criteria (see baseline characteristics in Table 1).
- cognitively normal seniors and is recognized to be influenced by several factors including age, disease severity, general debility, and gender.
- The average proportion of drug use over study period was 0.49 (SD 0.3) and by quartile was 0.33 (25%), 0.55 (50%), 0.75 (75%), and 0.99 (100%).
- Over the entire course of the study 12% never took any antidementia drugs.
- The median difference in survival between the lowest quartile group and the most persistent or highest quartile group was 3.12 years.
- Male sex (p<.0001), age (p<.0001), moderate vs. mild (p<.01) and severe vs. mild (p<.01) stage disease, drug use before the initial visit (p<.001) were associated with higher mortality. Longer duration of symptoms at the initial visit was associated with a decreased risk of death (p=.001).
- Patients whose drug use fell in the lowest three quartiles had a significantly increased relative risk of death compared to the highest quartile of drug use with adjustments: HR (1st) = 2.4 (95% CI 1.3-4.7); HR (2nd) = 2.2 (95% CI 1.5-3.2, p<.001); HR (3rd) = 1.5 (95% CI 1.0-2.2, p<.05) (see Figure 1).
- Women modeled included preprogression rate instead of baseline MMSE and duration of symptoms, drug use before the initial visit was not associated with increased risk of death (p=0.17), suggesting that rapid progressors were more likely to use drug early. The persistency score (continuous variable) remained inversely and significantly associated with decreased risk of death: HR = 0.6, (95% CI 0.39-0.89, p<.05).

Survival Analysis

- Table 2 — Cox model unadjusted HRs and 95% CIs for each quartile
- Figure 1. Time to Death by Persistency Score (1st, 2nd, 3rd, and 4th Quartiles)

References